Exchange: NASDAQ·Updated 05:27 PM EDT
News
all
press releases
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
Twist Bioscience Corporation (Nasdaq: TWST) (Twist), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per share. All of the shares of common stock to be sold...
Business Wire
More News
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
Twist Bioscience Corporation (Nasdaq: TWST) (Twist), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up...
Business Wire
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (Twist or the Company), a mid-cap growth and value biotech company, today announced that a total of 44,434 restricted stock units (RSUs) will be granted to 24 recently hired individuals, in each case as...
Business Wire
Twist Bioscience Sees AI Drug Discovery Pipeline Expand
Twist Bioscience (NASDAQ: TWST) stock is up on strong Q3 results and raised guidance. AI drug discovery and NGS businesses show growth.read more...
Benzinga
Twist Bioscience (TWST) Reports Q3 Loss, Beats Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of -12.00% and +3.39%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the third quarter fiscal 2026 ended June 30, 2026. Visit the Events and Presentations page of the Investor Relations section under the Company tab...
Business Wire
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of 0.00% and +7.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Alpha Cognition Inc. (ACOG) Surges 8.6%: Is This an Indication of Further Gains?
Alpha Cognition Inc. (ACOG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
Twist Bioscience (TWST) Surged on Strong Results and AI Drug Discovery Demand
Twist Bioscience (TWST) Surged on Strong Results and AI Drug Discovery Demand...
Yahoo! Finance: News
Cathie Wood Is Selling This High-Flying Stock. Is It a Buy?
Key PointsOn June 30, Cathie Wood's Ark ETFs sold over $11 million worth of stock in Twist Biosciences...
Nasdaq News: Markets

Advertisement|Remove ads.